-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 12th, AstraZeneca announced that the PARP inhibitor olaparib (Lynparza) jointly developed by the company and Merck & Co.
The FDA approval is based on a Phase 3 clinical trial called OlympiA
The latest clinical trial results show that olaparib also provides a statistically significant and clinically meaningful improvement in patients' overall survival
Breast cancer is one of the most common cancers worldwide, with more than 2.
BRCA is an important protein for repairing cellular DNA damage, and PARP also plays an important role in repairing DNA damage
Previously, it has been approved by the US FDA for the treatment of advanced ovarian, breast, pancreatic and other cancer types carrying germline BRCA mutations
Professor Andrew Tutt, Global Head of Clinical Trials at OlympiA and Professor of Oncology at the Institute of Cancer Research and King's College London, said: "Today's approval of olaparib is good news for patients with certain genetic types of breast cancer
References:
[1] Lynparza approved in the US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer.
